摘要
依照美国CMS保险给付的规定,葡萄糖正子扫描在头颈部癌症病人适用在肿瘤的诊断、分期和再分期。这个标准自2001年7月到2009年4月为止,没有变动过。随着个人化医疗的来临、影像学的进步和标靶治疗发展,我们以口腔癌为例,在现阶段的标准之下提出探讨,并且以未来葡萄糖正子扫描在肿瘤临床运用,提出新方向和新思维。
Based on the criteria from Center of Medicare and Medicaid Services （CMS） in the United States, FDG PET was reimbursed in head and neck cancer for diagnosis, staging and restaging since July 1st, 2001. However, with the development of targeting therapy and new medical instruments for personalized treatment planning in cancer patients, the indications of the coverage for PET scan in head and neck cancer were not changed so far. In this review, we will discuss the impacts of PET in oral cavity cancer, based on the coverage of CMS addressed in Apr.7, 2009. We will also show potentials of PET scans in oral cavity cancer trying to give some new direction in the applications of oncology in the future.
出处
《中国医疗设备》
2009年第8期12-16,共5页
China Medical Devices
